3-[7-[(4-methylimidazol-2-ylamino)methyl]-1-(2-phenylethyl)-6,8-difluoroquinoline-4-one-3-ylcarbonylamino]-2-((2,4,6-trimethylphenyl)sulfonylamino)propionic acid | 208580-95-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-[7-[(4-methylimidazol-2-ylamino)methyl]-1-(2-phenylethyl)-6,8-difluoroquinoline-4-one-3-ylcarbonylamino]-2-((2,4,6-trimethylphenyl)sulfonylamino)propionic acid
• 英文别名: 3-[[6,8-difluoro-7-[[(5-methyl-1H-imidazol-2-yl)amino]methyl]-4-oxo-1-(2-phenylethyl)quinoline-3-carbonyl]amino]-2-[(2,4,6-trimethylphenyl)sulfonylamino]propanoic acid
• CAS: 208580-95-4
• 化学式: C₃₅H₃₆F₂N₆O₆S
• 分子量: 706.77
• InChiKey: SBLWMPQXSQRKPS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  50
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  182
• 氢给体数：
  5
• 氢受体数：
  12

文献信息

• Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
  申请人：——

  公开号：US20030103898A1

  公开（公告）日：2003-06-05

  The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin receptor targeted imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and c) forming an image from the detection of said vitronectin targeted imaging agent and said perfusion imaging agent.

  本发明描述了一种哺乳动物同时成像的方法，包括：a）向该哺乳动物注射一个靶向vitronectin受体的成像剂和一个灌注成像剂；并b）同时检测vitronectin受体靶向成像剂与vitronectin受体结合以及灌注成像剂；并c）从检测到的vitronectin靶向成像剂和灌注成像剂形成图像。
• Integrin targeted imaging agents
  申请人：Barnes Jewish Hospital

  公开号：EP2269659A1

  公开（公告）日：2011-01-05

  Emulsions preferably of nanoparticles formed from high bioling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for QvP3 integrin, other than an antibody. The nanoparticles may further include biologically active agents, radionuclides, or other imaging agents.

  最好是由高生物活化液体全氟化学物质形成的纳米颗粒乳液，所述颗粒涂有脂质/表面活性剂涂层，通过将所述纳米颗粒与特异于 QvP3 整合素的配体（抗体除外）偶联，使其特异于活化的内皮细胞区域。纳米颗粒可进一步包括生物活性剂、放射性核素或其他成像剂。
• Vitronectin receptor antagonist pharmaceuticals
  申请人：——

  公开号：US20020041878A1

  公开（公告）日：2002-04-11

  The present invention describes novel compounds of the formula: (Q) d -L n -C h , useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

  本发明描述了式中的新型化合物： (Q) d -L n -C h , 用于诊断和治疗癌症、患者肿瘤成像方法和患者癌症治疗方法。本发明还提供了用于监测治疗性血管生成治疗和新血管生成血管破坏的新型化合物。本发明进一步提供了用于动脉粥样硬化、再狭窄、心脏缺血和心肌再灌注损伤成像的新型化合物。本发明还进一步提供了用于治疗类风湿性关节炎的新型化合物。这些药物由与血管生成过程中上调的受体结合的靶向分子、任选连接基团和治疗有效的放射性同位素或诊断有效的可成像分子组成。可成像分子是伽马射线或正电子发射的放射性同位素、磁共振成像造影剂、X 射线造影剂或超声造影剂。
• VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS
  申请人：——

  公开号：US20020182147A1

  公开（公告）日：2002-12-05

  The present invention describes novel compounds of the formula: (Q) d —L n —C h , useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

  本发明描述了式中的新型化合物： (Q) d -L n -C h , 用于诊断和治疗癌症、患者肿瘤成像方法和患者癌症治疗方法。本发明还提供了用于监测治疗性血管生成治疗和新血管生成血管破坏的新型化合物。本发明进一步提供了用于动脉粥样硬化、再狭窄、心脏缺血和心肌再灌注损伤成像的新型化合物。本发明还进一步提供了用于治疗类风湿性关节炎的新型化合物。这些药物由与血管生成过程中上调的受体结合的靶向分子、任选连接基团和治疗有效的放射性同位素或诊断有效的可成像分子组成。可成像分子是伽马射线或正电子发射的放射性同位素、磁共振成像造影剂、X 射线造影剂或超声造影剂。
• NOVEL INTEGRIN RECEPTOR ANTAGONISTS
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP0944619B1

  公开（公告）日：2006-10-11